Citadel Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Citadel Advisors’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-134,667	Closed	-$1.22M	–	8264
2013 Q4	$1.22M	Sell	134,667 -49,153	-27%	-$355K	﹤0.01%	3026
2013 Q3	$1.16M	Sell	183,820 -293,177	-61%	-$1.86M	﹤0.01%	2948
2013 Q2	$3.25M	Buy	+476,997	New	+$3.32M	0.01%	1983

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Citadel Advisors's CADX Position: Q1 2014 in Review

Citadel Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 134,667 shares — an estimated $1.22M sold.

Citadel Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $3.25M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Citadel Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Citadel Advisors sold 134,667 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.22M.
Citadel Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Citadel Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $3.25M in Q2 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Citadel Advisors's 13F filing for Q1 2014, filed 15 May 2014.